Three months supplementation of hyperhomocysteinaemic patients with folic acid and vitamin B6 improves biological markers of endothelial dysfunction.
Hyperhomocysteinaemia is a risk factor for premature atherosclerosis and venous thromboembolic disease. Supplementation with folic acid and vitamin B6 has been shown to decrease plasma homocysteine but data fail to assess an effect on the progression of vascular disease. We measured plasma homocysteine and two markers of endothelial injury (plasma soluble thrombomodulin and von Willebrand factor) at baseline and after 3 months of treatment with folic acid and vitamin B6. After this treatment there was a significant decrease in fasting soluble thrombomodulin (-15 ng/ml, 95%CI 5-22.2). Von Willebrand factor was significantly raised after methionine load at baseline but did not significantly rise after supplementation.
Constans
J
J
Service de Médecine Interne et Pathologie Vasculaire, Hôpital Saint-André, Bordeaux, France. joel.constans@chu-aquitaine.fr
Blann
A D
AD
Resplandy
F
F
Parrot
F
F
Renard
M
M
Seigneur
M
M
Guérin
V
V
Boisseau
M
M
Conri
C
C
D000328:Adult; D004730:Endothelium, Vascular; D005260:Female; D005492:Folic Acid / Q000008:administration & dosage*; D006710:Homocysteine / Q000097:blood; D006801:Humans; D020138:Hyperhomocysteinemia / Q000178:diet therapy*; D008297:Male; D008875:Middle Aged; D011736:Pyridoxine / Q000008:administration & dosage*; D012307:Risk Factors; D018180:Thrombomodulin / Q000097:blood; D014652:Vascular Diseases / Q000209:etiology*; D014841:von Willebrand Factor / Q000032:analysis
D018180:Thrombomodulin; D014841:von Willebrand Factor; D006710:Homocysteine; D005492:Folic Acid; D011736:Pyridoxine